The short answer: what the right patient looks like

For most adults with cartilage damage — whether a single focal lesion or widespread joint wear — ChondroFiller® is likely worth discussing at assessment. Delivered as an ultrasound-guided outpatient injection, it requires no theatre admission, no general anaesthetic, and no surgical incision, which immediately sets it apart from the surgical cartilage repair options many patients have been told are their only route.

The injection pathway is deliberately inclusive. There is no documented upper age limit and no defect-size ceiling: the collagen scaffold can coat a small contained lesion or the entire articular surface in a single appointment. Active patients in their 60s, 70s, and beyond qualify — the treatment is specifically positioned as a joint-preservation step for people who are not yet ready, or not willing, to proceed to joint replacement.

Three factors carry the most weight when a clinician reviews a case: the character of the cartilage damage on MRI, whether the joint is mechanically stable (no unaddressed ligament laxity or significant malalignment), and whether the patient holds realistic expectations — ChondroFiller® supports the body's own repair processes through acellular matrix-induced chondrogenesis rather than offering guaranteed regeneration. Subsequent sections work through each of those factors in detail.

Defect type, size, and joint location

Cartilage damage takes two broad forms, and the injection pathway accommodates both. A contained focal defect — the clinician's term for a discrete area of cartilage loss with intact surrounding cartilage acting as a border — is the clearest indication. That surrounding rim matters because the collagen scaffold is injected as a liquid and gels in situ; physical containment keeps the material within the damaged zone while the body's own progenitor cells migrate in from the synovium and subchondral bone to begin repair. Where the defect edges are less defined, or where wear is more diffuse across the joint surface, the injectable route can still be appropriate — including in Kellgren-Lawrence Grade III or IV osteoarthritis, a severity that typically exceeds the selection criteria for arthroscopic cartilage surgery, which commonly caps defect size at 4–6 cm².

Subchondral bone quality is assessed alongside defect geometry during the imaging-led workup. Because the scaffold relies on cell recruitment from below the cartilage layer, changes to that underlying bone — oedema, cystic change, sclerosis — are factored into the clinician's judgement about how well the repair process is likely to be supported.

Joint location is rarely a disqualifying factor in itself. Knee, hip, and ankle account for the majority of cases. Shoulder, elbow, wrist, foot, and hand have also been treated, most often for focal post-traumatic or sports-related lesions.

Patient factors: age, activity level, and OA grade

The two clearest patient profiles in the clinical literature illustrate how wide the injection pathway runs. In the Bulgarian prospective cohort, patients had a mean age of 31 and presented with focal sports-related chondral lesions — the kind of isolated defect where cell recruitment from surrounding healthy tissue is most predictable. At the other end of the age and severity spectrum, a 2025 prospective trial extended the injection approach to Grade IV knee osteoarthritis, a population previously channelled towards arthroplasty. Both groups showed measurable improvement, but the confidence levels are not equal: the focal-defect, younger-patient data sits on firmer comparative ground, while the Grade IV OA evidence is early-stage and still maturing.

That distinction has practical implications. Younger patients with post-traumatic or sports lesions can generally expect fewer competing biological variables during repair. For older patients with advanced joint wear, the scaffold still offers a joint-preservation route where surgery is not desired or medically appropriate — but realistic expectations become more important, not less. Subchondral bone condition and the extent of diffuse wear affect how well the body's own progenitor cells respond to the collagen matrix.

No specific BMI threshold appears in the available evidence for the injection pathway. Theatre fitness is simply not a criterion — the treatment is delivered as an outpatient injection under ultrasound guidance, which means surgical and anaesthetic risk profiles are irrelevant to eligibility. This opens the injectable route to patients excluded from arthroscopic candidacy for medical rather than cartilage-related reasons.

Individual eligibility is confirmed through imaging-led specialist assessment, which can weigh bone quality, defect geometry, and clinical history together rather than applying a single threshold.

Joint conditions that must be addressed first

Scaffold integration depends on the mechanical environment as much as on the biology of the defect itself. A collagen matrix injected into a joint that is overloaded, unstable, or structurally misaligned will face forces it cannot withstand before the body's own cells have had time to establish within it — the repair process is undermined before it begins.

Three conditions in particular demand attention before or alongside treatment: ligament instability, significant malalignment, and meniscal deficiency. Ligament laxity alters how load is distributed across the joint surface. A leg that is bowed or angled in a way that concentrates weight through the damaged zone — what clinicians call malalignment — produces the same problem from a different cause. Loss of meniscal tissue removes one of the joint's main shock-absorbing and load-sharing structures. In each case, the underlying mechanical fault will continue to stress the repair site irrespective of what is placed within it.

None of these factors represents a permanent reason treatment cannot happen. Once addressed — whether through ligament repair, realignment correction, or concurrent management of the meniscal problem — ChondroFiller candidacy can be revisited. They are prerequisites, not disqualifications.

Identifying them is part of the imaging-led clinical assessment. This is one reason suitability cannot be determined without a specialist review of scans and physical examination: mechanical contributors to cartilage damage are not always obvious from symptoms alone.

Who is not suitable: contraindications and cautions

Three circumstances prompt a clinician to pause before recommending ChondroFiller® injection.

Active infection — whether localised within the joint or systemic — is the clearest absolute deferral. Introducing a collagen scaffold before infection has cleared is not appropriate; once the infection is resolved, assessment can resume. It is a timing issue, not a permanent bar.

Collagen allergy warrants careful disclosure. The scaffold is composed of murine-derived Type I collagen, so any known sensitivity to collagen or to mouse-derived materials must be raised before treatment is planned. This does not automatically exclude a patient, but it requires specialist review to weigh the individual risk.

Unrealistic expectations form a clinical caution rather than a medical contraindication. Outcomes vary by defect location, size, and individual biology; patients who expect a guaranteed regenerative result risk disappointment even when treatment proceeds technically well. Honest expectation-setting is part of the pre-treatment consultation, not an optional add-on.

Significant structural instability or malalignment that cannot be addressed concurrently also belongs in this list. Where any of these factors appears to apply, raising it at consultation is the right starting point — several are resolvable with appropriate preparation, and a specialist can distinguish those that genuinely preclude treatment from those that simply need to be addressed first.

How suitability is confirmed: assessment and next steps

Confirming suitability involves more than running through a checklist. At a formal assessment, the clinician combines MRI review with physical examination to build a complete picture: defect geometry, subchondral bone condition, joint mechanics, and the patient's activity goals are considered together rather than in isolation. That integrative view is why self-assessment tools — however detailed — cannot substitute for a specialist consultation.

Outcome data from published studies provides a framework for that conversation. IKDC scores in knee cases have improved by approximately 30 points in clinical series; comparable mHHS gains have been reported for hip treatment; MOCART scores in the 70–87 range and a complication rate approaching zero offer useful benchmarks when weighing ChondroFiller® against other options. Where long-term follow-up is concerned — particularly for the injection pathway in advanced osteoarthritis — evidence beyond three years is still accumulating, and a clinician working from the current literature will say so clearly rather than overstate what is known.

For patients in London considering ChondroFiller® injection, the London Cartilage Clinic on Harley Street provides specialist assessment as the appropriate practical starting point — consultations can be arranged through londoncartilage.com.

1. [1] Joint Preservation in Patients with Grade IV Osteoarthritis of the Knee: Use of an Acellular Collagen Scaffold (ChondroFiller® Liquid) and Blood Derived Stem Cell Rich Graft — A Prospective Controlled Trial. (2025). https://doi.org/10.29011/2575-9760.011360 https://doi.org/10.29011/2575-9760.011360
2. [2] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
3. [3] Emerging Strategies in Cartilage Repair and Joint Preservation. (2024). https://doi.org/10.3390/medicina61010024 https://doi.org/10.3390/medicina61010024